Telmisartan

What it is

Telmisartan belongs to the angiotensin II receptor blockers, sartans for short. In the EU it has been approved as Micardis since December 16, 1998; today there are numerous generics. It is approved for the treatment of high blood pressure in adults and for reducing cardiovascular risk in people with established vascular disease or type 2 diabetes with organ damage.

According to the summary of product characteristics, telmisartan is a specific blocker of the AT1 receptor. In humans, 80 mg almost completely inhibits the rise in blood pressure triggered by angiotensin II; the effect lasts for over 24 hours. The half-life is more than 20 hours, which is why one tablet per day is sufficient.

How it is supposed to work

The first effect is the familiar one: angiotensin II constricts vessels, drives up aldosterone and promotes remodeling processes in the heart, kidneys and vessel wall. Blocking the AT1 receptor lowers blood pressure and organ strain. This is supported in humans all the way to hard endpoints.

The second effect is what makes telmisartan interesting for biohackers. In 2004, a paper in Hypertension showed that telmisartan acts in the laboratory as a partial agonist of PPAR-gamma. This is the same nuclear receptor targeted by the glitazone group of diabetes drugs, and it controls fat and sugar metabolism. In rats on a high-fat, high-sugar diet, glucose, insulin and triglycerides fell. Other sartans did not activate PPAR-gamma at the usual blood concentrations.

A 2011 mouse study went further: telmisartan slowed weight gain, increased running endurance and raised the proportion of enduring, slow muscle fibers, mediated via PPAR-delta and the energy-sensing enzyme AMPK. In mice without PPAR-delta, the effect was absent. From such findings arose the image of a blood pressure drug with a built-in metabolic and training bonus.

Why the longevity scene is paying attention

In aging research, the renin-angiotensin system is considered a driver of age-related changes. A 2024 review summarizes that blocking it attenuates such changes in several mammalian species and extends lifespan in rodents, among other things via AMPK, mTOR and the mitochondria. The authors therefore propose clinical trials with ACE inhibitors and sartans against aging. A drug that addresses both, is well tolerated and has been on the market for decades sounds like an ideal candidate. In user circles, telmisartan is therefore also discussed by people without a classic indication. That is off-label and belongs in the hands of a physician, not least because it can lead to dizziness and circulatory problems with normal blood pressure.

What the studies show

TRANSCEND: telmisartan versus placebo

5,926 high-risk patients who did not tolerate ACE inhibitors received 80 mg telmisartan or placebo for a median of 56 months. Blood pressure was 4.0/2.2 mmHg lower under telmisartan. The primary endpoint occurred in 15.7 versus 17.0 percent and missed significance. The narrower endpoint of cardiac death, heart attack and stroke was slightly more favorable at 13.0 versus 14.8 percent, but no longer significant after correction for multiple testing.

PRoFESS: diabetes and stroke

20,332 people after an ischemic stroke received 80 mg telmisartan or placebo for an average of 2.5 years. A recurrent stroke occurred in 8.7 versus 9.2 percent, not significant. New diabetes occurred in 1.7 versus 2.1 percent, also not significant. A substudy found no influence on cognitive performance or dementia.

TELEX: walking distance in circulatory disorders

114 people with peripheral artery disease received telmisartan or placebo for 6 months, some with walking exercise. The 6-minute walking distance did not improve under telmisartan; the adjusted difference was -16.8 m in favor of placebo. In muscle biopsies from 13 participants who exercised, telmisartan was associated with larger muscle fibers, more satellite cells, less myostatin and activated PPAR-gamma signaling pathways. This is exploratory, but so far the most direct indication of the PPAR mechanism in human muscle.

The mouse lifespan program ITP

The US Interventions Testing Program tests substances in genetically heterogeneous mice at 3 sites. In the round published in 2026, the combination of atorvastatin and telmisartan extended lifespan in neither male nor female animals. Telmisartan alone was not tested in this round.

Where the data stop

For a longer life there are no data in humans, and the only rigorous lifespan test in mice was negative. The PPAR-gamma mechanism has been shown in cells and rodents, in humans only indirectly via insulin values, visceral fat and a small biopsy substudy. The summary of product characteristics does not mention PPAR-gamma. Where hard endpoints mattered, the metabolic advantage did not materialize. New diabetes did not become significantly less frequent in PRoFESS. In fatty liver, a meta-analysis of 6 trials with 258 participants found no consistent improvements in weight, HOMA-IR, blood lipids or liver values. Telmisartan protected memory neither in PRoFESS nor in the joint analysis of ONTARGET and TRANSCEND. The increase in endurance comes from mice; in people with circulatory disorders, walking distance did not improve. There are no studies for healthy people with normal blood pressure.

Status, approval and legal

Telmisartan is an approved, prescription-only medicine in Germany and the EU: the original Micardis since 1998, plus many generics and, since 2002, the combination with the diuretic hydrochlorothiazide. It is approved for high blood pressure and for cardiovascular prevention in high-risk patients. Any use for longevity, metabolic optimization or performance enhancement is off-label. The large endpoint trials used 80 mg per day; this is a study detail, not a recommendation. Telmisartan is not on the World Anti-Doping Agency’s prohibited list, but combination products with hydrochlorothiazide contain a diuretic that is banned under S5.

Safety

In controlled trials, side effects overall were about as frequent as under placebo, 41.4 versus 43.9 percent. Typical are dizziness, low blood pressure, elevated potassium and a deterioration of kidney function, rarely angioedema, including of the intestine, and allergic reactions. In the second and third trimesters of pregnancy, telmisartan is prohibited because sartans harm the unborn child; in the first trimester it is not recommended. Further contraindications are biliary obstruction and severe hepatic impairment. In ONTARGET, the combination with a second inhibitor of the renin-angiotensin system brought no additional benefit, but more kidney dysfunction, 13.5 versus 10.2 percent. Caution applies with lithium, potassium supplements and potassium-sparing agents. A cancer signal discussed in 2010 was not confirmed in the analysis of 15 trials with 138,769 participants.

Sources

• ONTARGET Investigators, N Engl J Med 2008 – telmisartan, ramipril or both
• TRANSCEND Investigators, Lancet 2008 – telmisartan in ACE inhibitor intolerance
• Yusuf et al., N Engl J Med 2008 – PRoFESS, telmisartan after stroke
• Benson et al., Hypertension 2004 – telmisartan as a partial PPAR-gamma agonist
• Feng et al., J Cell Mol Med 2011 – running endurance in mice via PPAR-delta
• Takagi and Umemoto, J Am Soc Hypertens 2014 – meta-analysis on insulin resistance
• McDermott et al., JAMA 2022 – TELEX, walking distance in peripheral artery disease
• Korstanje et al., Geroscience 2026 – ITP, no lifespan extension
• ARB Trialists Collaboration, J Hypertens 2011 – no increased cancer risk
• EMA – Micardis, product information (German)